Company intelligence / Profile preview

SUSMED

Ownership: Private
Development stage: Other

Overview

SUSMED has developed a digital therapeutic application for insomnia that delivers cognitive behavioral therapy for insomnia (CBT-I) via an app. This product received regulatory approval as a medical device in Japan. The company also provides a proprietary platform to support efficient clinical trials using blockchain and AI analytics, aiming to optimize drug development costs and improve data integrity. Additional pipeline programs are under development but have not yet reached commercialization.

Therapeutic areas: PsychiatryOther
Modalities: Device (Digital therapeutics app)Non-pharmacological therapyPlatform technology for clinical trials and digital health apps
Industry: Digital Health Medical Devices

Partnerships

Sumitomo Corporation/Summit Pharmaceuticals International CorporationCMIC GroupAculys Pharma

Beyond the preview

Go deeper on SUSMED.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SUSMED.

Explore the full profile